Halaven (eribulin mesylate) / Eisai, Knight Therap, Shenzhen Kexing Pharma - LARVOL DELTA

Minimal important differences in the EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: Results from a randomized trial (ESMO Asia 2025) - "Between June 2016 and October 2019, 302 female patients with HER2-negative metastatic breast cancer were enrolled across 50 institutions and randomized to receive either eribulin or S-1... This study identified MIDs for the QLQ-C30 and QLQ-BR23 in Japanese patients with metastatic breast cancer. These findings may help clinicians and researchers in interpreting changes in QOL scores."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Triple-negative breast cancer with somatic BRCA1 mutation and metaplastic progression in a young woman: A case report (ESMO Asia 2025) - "She underwent modified radical mastectomy with sentinel lymph node biopsy, followed by adjuvant doxorubicin–cyclophosphamide (AC) for 4 cycles, which was complicated by pneumonitis and heart failure. Weekly paclitaxel for 11 cycles was discontinued due to fatigue and elevated troponin, despite a normal ECG...She received gemcitabine–cisplatin for 2 cycles with stable disease, followed by cytoreductive palliative surgery with reconstruction, and then 2 additional cycles of gemcitabine–cisplatin...She was treated with docetaxel–capecitabine for 1 cycle with poor response, followed by sacituzumab govitecan for 3 cycles, which resulted in disease progression. Currently, the patient is on eribulin plus durvalumab, having completed 1 cycle...This case illustrates an unusual histological evolution from medullary carcinoma to metaplastic carcinoma, and subsequently to mucoepidermoid carcinoma. It raises important questions about the optimal timing of genomic testing and the..."

Case report • Clinical • IO biomarker • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer • BRCA • BRCA1 • HER-2 • PD-L1 • PGR • PTEN • RB1 • SF3B1 • STK11 • TMB • TP53

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=192 | Recruiting | Sponsor: Sun Yat-sen University | Enrolling by invitation ➔ Recruiting

Enrollment status • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

HydroLock: A versatile ADC platform with robust plasma stability, excellent bystander killing and superior in vivo efficacy (ESMO Asia 2025) - "Efficacies of Herceptin-GSC4903 and the potential to overcome DS8201 resistance were determined...We also conjugate eribulin to pertuzumab (Pertuzumab-GSC4781)... All these results warrant HydroLock as a novel and promising linker-payload platform for ADC development. HydroLock was leveraged in several bispecific ADC programs and the first IND submission is expected in late 2025."

Preclinical • Oncology

Combining anti-metabolic treatments with the repurposing of eribulin for glioblastoma: a clinical opportunity? (PubMed, Transl Cancer Res) - No abstract available

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: results from International, retrospective, real-world ADC-Low-Europe cohort. (SABCS 2025) - "We conducted an European, retrospective, real-world study in pts with HER2-low MBC who received Sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), either sequentially or not...The median progression-free interval (PFI) following ADC1 was 2.9 months [95% CI: 2.7-3.6] in the overall population, 2.7 months [95% CI: 2.5-3.5] with eribulin (n=79) and 4.2 months [95% CI: 2.7-5.7] with capecitabine (n=30).At ADC2 initiation, 81.3%, 7.6% and 22.7% of the pts had visceral, bone-only and brain/meningeal metastases, respectively...These results highlight the need: first to develop biomarkers to better identify pts that could be sensible to a second TOPO1-ADC; second to better select the choice of ADC1 since it has the greatest impact on natural history. About 150 additional pts from French and European centers are currently being enrolled and will be included to the final presentation."

Metastases • Real-world • Real-world evidence • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=792 | Recruiting | Sponsor: Hoffmann-La Roche | N=580 ➔ 792 | Trial completion date: May 2028 ➔ Sep 2030 | Trial primary completion date: May 2028 ➔ Sep 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PIK3CA

Poor response to systemic therapy upon progression on cyclin dependent kinase 4/6 inhibitors in HR+ Inflammatory Breast Cancer (SABCS 2025) - "RESULTS Among N = 33 patients evaluated, upon progression on standard of care CDKI and endocrine directed therapy (ET) combinations, patients received the following therapies with median ToT (months (min-max ToT)), respectively: capecitabine (N = 7; 3 (2-5)), everolimus/ET (N = 6, 3 (1-4)), Abraxane (N = 3, 3(2-10)), Eribulin (N = 2, 2.5(2-3)), capivasertib/fulvestrant (N = 1, 6(6)), taxol (N = 1, 5(5)), elacestrant (N = 1, 3(3)), fulvestrant (N = 1, 3(3)), tamoxifen (N = 1, 1(1)), intrathecal topotecan (N = 1, 1(1)), non standard/clinical trial (N = 4, 2.5(1-4)). CONCLUSION Patients with metastatic HR+ IBC demonstrate poor response to ET and cytotoxic chemotherapies upon progression on first line standard CDKI/ET, with a disproportionately high rate of death occurring in the first line setting due to advanced disease. Given previously reported low ToT on CDKI/ET in the first line and high incidence of brain relapse in this population, clinical trial design utilizing..."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • HER-2

Cytokine score based on expression levels of multiple cytokines is a prognostic indicator in metastatic breast cancer patients treated with chemotherapy (SABCS 2025) - " Of the patients, 46.5% (n = 20) were treated with eribulin, 9.3% (n = 4) with trastuzumab deruxtecan, 9.3% (n = 4) with paclitaxel and bevacizumab, 7.0% (n = 3) with trastuzumab emtansine, and 27.9% (n = 12) with other chemotherapeutic agents. Our results show that the levels of TNF-α, sIL-2R, IL-6, and TK1 were associated with outcomes in patients with MBC treated with chemotherapy. The cytokine score, based on the number of elevated cytokines, is an important prognostic indicator for both OS and PFS. Furthermore, since a high cytokine score was associated with higher levels of MDSCs, and lower levels of CD4+ and CD8+ lymphocytes, the cytokine score might be associated with patient outcomes through immune reaction."

Biomarker • Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor • CD4 • CD8 • CXCL8 • IL2 • IL6 • TGFB1 • TNFA

A Rapid Digital Patient-Derived Organoid Guiding Therapy After Antibody Drug Conjugates (ADC)s In Patients with Metastatic Breast Cancer[YY1] [YY1]The size limit (including title and body) is 3,400 characters; this does not include spaces. (SABCS 2025) - "Currently FDA-approved ADCs such as trastuzumab deruxtecan (T-DXd) or sacituzumab govitecan (SG) are routinely used in clinical practice, but data on optimal sequencing of these agents for individual patients are lacking...DPO was then subjected to ADCs (T-DXd, SG, Dato-DXd) or chemotherapy drug (Gemcitabine; Carboplatin; Eribulin) dosing experiments to determine drug sensitivities (AUC values calculated from CTG readouts) for downstream correlation analyses... The DPO platform shows promise in predicting treatment responses and differentiating resistance mechanisms to ADCs in MBC. This approach provides a foundation for rational selection among different ADCs and chemotherapies, especially after acquired resistance to prior ADC treatment, in patients with advanced breast cancer."

Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor • YY1

Economic Impact of Adverse Event Management in HR+/HER2− Metastatic Breast Cancer: A Comparative Analysis of Datopotamab deruxtecan and standard of care in the Brazilian Private Healthcare System (SABCS 2025) - " The therapeutic regimens analyzed in this study were derived from two pivotal clinical trials: TB01, which compared Dato-DXd with ICC: (capecitabine, eribulin, gemcitabine, vinorelbine), and TROPICS-022, which assessed sacituzumab govitecan (SG) versus ICC. This analysis identified differences in AE-related costs across treatment modalities, emphasizing the economic relevance of toxicity management in patients with HR+/HER2− metastatic breast cancer who have progressed on endocrine therapy and received at least one line of systemic treatment. Dato-DXd demonstrated lower expenditures associated with adverse event management compared to its respective ICC arm comparator. SG was associated with higher AE-related costs relative to its respective ICC arm comparator."

Adverse events • HEOR • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769) (SABCS 2025) - P2 | " This is a randomized phase II trial; 201 patients (pts) will be randomized in a 1:1:1 fashion to enza, enza plus mif, or TPC (carboplatin, paclitaxel, eribulin, or capecitabine). As of 7/9/2025, 19 of 201 pts have begun protocol-specified tx. This trial is supported by the Translational Breast Cancer Research Consortium, The Breast Cancer Research Foundation, The TaTa Sisterhood Foundation, Pfizer/Astellas, and Corcept Therapeutics."

Clinical • IO biomarker • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AR • CTCs • ER • HER-2 • PGR

OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - P3 | N=254 | Active, not recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 ➔ Jun 2027

Trial completion date • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • BRCA2 • HER-2 • PGR

Preliminary data from a global multicohort Phase2 randomized trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy for 1L/2L+ locally advanced/metastatic TNBC (SABCS 2025) - P2, P3 | " In this global Phase 2, randomized, open-label, multicohort trial (NCT06449222), Cohort 1 enrolled patients (pts) with 1L/2L+ LA/mTNBC (50% cap of 2L+ TNBC) who received pumitamig (15 or 20 mg/kg IV Q2W) + nab-paclitaxel until disease progression/unacceptable toxicity. In Cohort 2, pts received the flat dose equivalent of 20 mg/kg pumitamig IV: Arm 1: 1400 mg Q2W + paclitaxel; Arm 2: 2000 mg Q3W + gemcitabine + carboplatin; Arm 3: 2000 mg Q3W + eribulin... Pumitamig + chemotherapy showed encouraging efficacy independent of CPS levels and manageable safety in 1L/2L+ LA/mTNBC. The efficacy is particularly clinically meaningful in pts with CPS <10, addressing a critical unmet need. No new safety signals were seen compared to previously characterized safety profile of pumitamig."

Clinical • IO biomarker • Metastases • P2 data • Breast Cancer • Triple Negative Breast Cancer • PD-L1

A comparative study of trastuzumab and pertuzumab combination subcutaneous and intravenous infusion in patients with HER2-positive breast cancer: a retrospective and prospective combined study of time efficiency, cost-effectiveness, quality of life, and socioeconomic impact (SABCS 2025) - "When combined with docetaxel, the median was 213.0 minutes (95% CI 181.6-256.8) in the IV group, SC group was 167.5 minutes (95% CI 134.6-236.6). When combined with eribulin, the median was 198.0 minutes (95% CI 160.8-266.2) in the IV group and 107.0 minutes (95% CI 83.6-164.7) in the SC group... The SC formulation of trastuzumab and pertuzumab may be a useful treatment option for HER2-positive breast cancer, improving time efficiency and patient satisfaction."

Cost effectiveness • HEOR • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

AGNOSTIC INDICATION OF IMMUNE CHECKPOINT INHIBITORS (ICI): PATTERNS OF RESPONSE OF SARCOMAS (CTOS 2025) - "9 patients for now are evaluable: 7 received single-agent pembrolizumab, 1 pembrolizumab/eribulin, and 1 ipilimumab/nivolumab. Although high TMB, dMMR and MSI-H status are uncommon in sarcomas, this small series suggests these cases can benefit from ICI. However, the best responses were observed in subtypes known to benefit from ICI regardless of their biomarker status. A larger study is needed to evaluate the predictive value of high TMB, dMMR, and MSI-H status across sarcoma subtypes."

Checkpoint inhibition • IO biomarker • Tumor mutational burden • Angiosarcoma • Brain Cancer • Leiomyosarcoma • Microsatellite Instability • Neurofibrosarcoma • Non-melanoma Skin Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • MSI • TMB

Epithelial-mesenchymal dynamics in cancer: Role of signalling pathways, stromal interactions and natural therapies. (PubMed, ADMET DMPK) - "Furthermore, marine-based compounds, including caprolactin C, laminaran sulfate, BFP-3, bryostatin 1, sinulariolide, manzamines, halichondrin B, eribulin and biemamides, exhibit significant anti-metastatic effects by targeting EMT-associated pathways. The diverse range of therapeutic molecules discussed in this review provides promising therapeutic avenues for developing targeted strategies against EMT in cancer."

Journal • Review • Oncology

Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. (SABCS 2025) - "Materials and Methods We evaluated the efficacy and toxicity of MELK-inhibitors (MELK-In-17, MELK-In-30e, and OTS167), alone or in combination with paclitaxel or eribulin, using the 4T1(TNBC) and SUM149 (TN-IBC) mouse models. These findings provide a rationale for further investigation into MELK-targeted combination therapies to enhance the efficacy of existing therapies and immune activation in aggressive cancers. We plan to assess the prognostic value of MELK, EMT, and immune markers based on mIF analysis of patient samples."

IO biomarker • Preclinical • Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD163 • CDH1 • CDH2 • FN1 • MELK • MRC1 • PD-L1 • VIM

Aretha trial: Safety run-in results of eribulin + evexomostat in metastatic triple-negative breast cancer with metabolic dysfunction (SABCS 2025) - P2 | "Evexomostat + eribulin safety was confirmed and the trial advanced to the randomization phase including a placebo-controlled arm with eribulin. Preliminary biomarker results indicate that insulin resistance was unchanged, and favorable changes were seen in other metabolic markers."

Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • LEP • METAP2 • RETN • VEGFC • VEGFD

The Utility of MT1-MMP in Predicting Treatment Efficacy with HER2-positive advanced or metastatic breast cancer: JBCRG-M06/EMERALD trial TR (SABCS 2025) - "The MT1-MMP score is unable to distinguish the combined trastuzumab and pertuzumab with eribulin mesylate or trastuzumab and pertuzumab with taxane therapy. However, it may be a prognostic factor for HER2-positive local advanced or metastatic breast cancer patients treated with the trastuzumab and pertuzumab combination and eribulin mesylate or taxane."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • MMP14

A global Phase III, randomized, double-blind trial of BNT327 plus chemotherapy (chemo) vs placebo plus chemo in patients (pts) with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSETTA Breast-01) (SABCS 2025) - P1/2 | "Pts are stratified by prior treatment with cancer immunotherapy in the neoadjuvant/adjuvant setting, on-trial chemo regimen, and geography, and randomized 1:1 to receive a combination treatment with BNT327 or placebo plus physician´s choice chemo (paclitaxel/nab-paclitaxel, gemcitabine plus carboplatin, or eribulin). Secondary endpoints include PFS by investigator, objective response rate, duration of response, disease control rate, OS and PFS rates, occurrence of treatment emergent adverse events (TEAEs), dose interruption, reduction, and discontinuation due to TEAEs, and changes in pt-reported outcomes.Statistical The primary endpoints, PFS per BICR and OS, will be compared between treatment arms using a stratified log-rank test. The hazard ratio for PFS and OS will be estimated via a Cox proportional hazards model, adjusted for the randomization stratification factors.Accrual: The trial aims to randomize ~558 pts across sites in North and South America,..."

Clinical • IO biomarker • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1

LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - P1/2 | N=30 | Completed | Sponsor: National Taiwan University Hospital | Active, not recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Oct 2025

Trial completion • Trial completion date • Leiomyosarcoma • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Phase I Study of Whole Brain Radiotherapy with Concomitant Eribulin for Advanced Breast Cancer Brain Metastasis (SNO 2025) - "Secondary endpoints include overall survival, progression-free survival, response rate, and MMSE. This study is recently enrolling in Japan (jRCT1031250065)."

Metastases • P1 data • Brain Cancer • Breast Cancer • Glioblastoma • Oncology • Palliative care • Solid Tumor

Jbcrg-m06/emerald post-hoc analysis by physician's choice of docetaxel or paclitaxel: efficacy and safety of eribulin mesylate vs taxanes combined with trastuzumab and pertuzumab as first-line for her2-positive locally advanced or metastatic breast cancer (SABCS 2025) - P3 | "No differences in efficacy (i.e. non-inferiority results) were observed based on type of T used. While AEs were generally similar between the E and T groups, regardless of type of T used, a higher incidence of peripheral sensory neuropathy was noted with PTX compared with E or DTX."

Clinical • Metastases • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case report. (PubMed, World J Surg Oncol) - "This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS."

Biomarker • IO biomarker • Journal • Tumor mutational burden • Genito-urinary Cancer • Immunology • Inflammatory Arthritis • Liposarcoma • Oncology • Peritoneal Cancer • Prostate Cancer • Retroperitoneal Sarcoma • Rheumatology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • PD-L1 • TMB